Pentoxifylline as a Steroid-Sparing Agent in Granuloma Annulare: A Rural Retrospective Study

Area of Science:

• Dermatology
• Immunology
• Internal Medicine

Background:

• Granuloma annulare (GA) is an inflammatory skin condition characterized by granuloma formation.
• Its exact cause is unknown, but it is associated with systemic diseases.
• Localized GA usually responds to corticosteroids, while generalized GA is often resistant to treatment.

Purpose of the Study:

• To investigate the clinical characteristics of Granuloma Annulare (GA).
• To assess the association between comorbidities and disease extent.
• To evaluate the efficacy of pentoxifylline in treating generalized GA.

Main Methods:

• A retrospective review of 102 patients with GA was performed.
• Data collected included demographics, GA subtype, treatment history, and comorbidities.
• Comorbidity prevalence was compared to state and national averages, and treatment responses were analyzed.

Main Results:

• The study included 102 patients, 79% female, with a mean age of 46.
• Generalized GA (46% of cases) showed higher rates of type 2 diabetes, hypothyroidism, and autoimmune diseases.
• Generalized GA was more treatment-resistant; pentoxifylline achieved a 64% response rate, outperforming other treatments.

Conclusions:

• Generalized GA is linked to more comorbidities and is harder to treat.
• Pentoxifylline demonstrates significant efficacy and may be a valuable first-line systemic treatment for refractory GA.
• Further multi-center research is required to confirm these findings and establish evidence-based treatment guidelines.